重要的消息有哪些 潘功胜主持召开金融支持实体经济座谈会 5月19日，中国人民银行行长潘功胜主持召开金融支持实体经济座谈会并讲话。金融监管总局副局长周亮出席会议并讲话。中国人民银行副行长宣昌能、邹 澜出席会议。 会议强调，要实施好适度宽松的货币政策，满足实体经济有效融资需求，保持金融总量合理增长。加力支持科技创新、提振消费、民营小微、稳定外贸等重 点领域，用好用足存量和增量政策，提高金融支持实体经济质效，支持经济结构调整、转型升级和新旧动能转换。强化货币政策执行和传导，维护市场竞争 公平秩序，推动金融服务实体经济和银行自身可持续发展的有机统一。有序推进人民币国际使用，提高贸易和投融资便利化水平。统筹发展和安全，坚决维 护国家金融安全。 前4个月公共财政收入累计降幅继续收窄 中央收入月度增幅由负转正 财政部公布2025年1—4月财政收支情况，印花税1614亿元，同比增长18.9%。其中，证券交易印花税535亿元，同比增长57.8%。 国家能源局：4月份全社会用电量7721亿千瓦时，同比增长4.7% 国家能源局5月20日发布4月份全社会用电量等数据。4月份，全社会用电量7721亿千瓦时，同比增长4.7%。1—4月， ...

Policy Trends - Recent COVID-19 infections show a slight increase in some regions, but the clinical severity has not changed significantly according to a Chinese CDC expert [2] Drug and Device Approvals - Changshan Pharmaceutical's nadroparin calcium injection has received a drug registration certificate from Belarus, used for treating venous thromboembolism and other related conditions [3] - Shanghai Pharmaceuticals announced that its rivaroxaban tablets have received approval from the US FDA, aimed at reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients, among other uses [4] Capital Markets - Shanghai Kejun Pharmaceutical Technology Co., Ltd. completed a B+ round financing exceeding 100 million yuan, with funds primarily allocated for the phase III clinical development of its core product CG-0255 in the cardiovascular field [5] Industry Developments - Jingyin Pharmaceutical and CRISPR Therapeutics have formed a strategic partnership to jointly develop and commercialize a long-acting siRNA therapy for thrombotic diseases [6] - Buchang Pharmaceutical's subsidiary signed a commissioned research agreement with Fubicheng Pharmaceutical for the development of MF59 adjuvant [7] - Sanofi and Pfizer entered into a licensing agreement for a bispecific antibody product targeting PD-1 and VEGF, with Pfizer gaining exclusive rights outside mainland China [9] Public Sentiment Alerts - Jinhua Co., Ltd. reported that shareholder Xinyu Jinyu has reduced its holdings by 133,500 shares, representing 0.035765% of the company's total share capital [10] - Fosun Pharma announced the resignation of its Senior Vice President Rong Yang for personal reasons, effective May 16, 2025 [11]

Core Viewpoint - Changshan Pharmaceutical (300255) has received a drug registration certificate for its product, Nadroparin Calcium Injection, from the Belarusian drug regulatory authority, valid until March 13, 2030. This approval is expected to positively impact the company's expansion into overseas markets [1]. Group 1 - The drug Nadroparin Calcium Injection is primarily used for the treatment of moderate to high-risk venous thromboembolism and the prevention of venous thromboembolic diseases [1]. - The registration approval in Belarus represents a significant step for the company in terms of international market penetration [1].